Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-AFRICA
PACTR202507787267309Phase 3Not yet recruiting
- Sponsor
- NCIRE - The Veterans Health Research Institute
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ischemic stroke and transient ischaemic attack (TIA) comparing Cilostazol with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular events. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cilostazol
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on PACTR202507787267309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507787267309.